---
layout: default
title: Cetrorelix
parent: 僅模型預測 (L5)
nav_order: 84
evidence_level: L5
indication_count: 10
---

# Cetrorelix
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Cetrorelix: From GnRH Receptor Antagonism to Predicted Hypertrichosis

## One-Sentence Summary

> Cetrorelix (DrugBank DB00050) is described in the evidence pack's own repurposing rationale as a GnRH receptor antagonist that suppresses LH/FSH secretion; no formal original-indication or market data is on file for this drug.
> The TxGNN model's top-ranked prediction is potential efficacy in **Hypertrichosis (disease)**,
> but this signal is currently supported by **0 clinical trials** and **0 publications**, placing it at the lowest confidence tier.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available — no indication data on file (`original_indications` is empty) |
| Predicted New Indication | Hypertrichosis (disease) |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 (model prediction only, no clinical/literature support) |
| Norway Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism of action data is not available for this drug (`original_moa` field is a data gap). However, the evidence pack's own repurposing rationale characterizes cetrorelix as a **GnRH receptor antagonist** that blocks pituitary GnRH signaling, thereby suppressing LH/FSH release and indirectly lowering gonadal steroid (androgen) output.

The top-ranked prediction, hypertrichosis, rests on the assumption that excess hair growth is androgen-driven — if true, suppressing gonadal androgens could theoretically reduce hair growth. However, the pack's own annotation explicitly flags this link as weak: **most hypertrichosis is not androgen-dependent**, so the mechanistic basis for this specific prediction is limited and largely speculative.

Notably, among the 10 candidates reviewed in this pack, **rank 10 — "centra precocious puberty 1" (central precocious puberty)** — has a substantially stronger mechanistic rationale: it is explicitly GnRH-dependent, and a GnRH receptor antagonist would act on the same axis as the current standard of care (GnRH agonists). It carries a lower TxGNN score but was advanced to decision stage S1 ("Research Question") rather than S0/Hold, reflecting this stronger biological plausibility. It may warrant separate investigation even though it is not the headline (rank 1) prediction.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Norway Market Information

No marketing authorizations are currently registered in Norway for this drug (market status: **Not Marketed**; 0 licenses on file).

---

## Safety Considerations

Please refer to the package insert for safety information. No key warnings, contraindications, or drug-drug interaction data are currently on file for this drug (DDI query status: not found).

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked prediction (hypertrichosis) is supported only by the TxGNN model score (L5), with zero clinical trials or publications, and its own mechanistic rationale is explicitly acknowledged as weak (most hypertrichosis is not androgen-dependent). No original indication, MOA, or safety data are on file to support any progression.

**To proceed, the following is needed:**
- TFDA/regulatory label warnings and contraindications (flagged as **Blocking** — currently prevents entry into S1 safety pre-evaluation)
- Confirmed mechanism of action via DrugBank or equivalent source (flagged as **High** severity — needed for mechanistic-relevance analysis)
- Original approved indication(s) and clinical positioning data
- If pursuing further: targeted literature/trial search specifically for **central precocious puberty (rank 10)**, given its stronger GnRH-dependent mechanistic coherence with cetrorelix's known pharmacology, despite currently having no direct evidence either
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

